Please assess the completion status of the following clinical trial:

Trial Title: Effects of Short-term Growth Hormone in HIV-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* previously diagnosed HIV infection~* Stable antiretroviral regimen for at least 12 weeks prior to enrollment~* Waist circumference \>/= 95cm and waist-to-hip ratio \>/= 0.94 for males or waist circumference \>/=94cm and WHR \>/= 0.88 for females, occurring in the context of treatment for HIV disease~* Subjective evidence of at least one of the following changes, occurring during the treatment of HIV disease: increased abdominal girth, relative loss of fat in the extremities, or relative loss of fat in the face~Exclusion Criteria:~* Use of anti-diabetic agents, Megace, testosterone, or any steroid use within 6 months of the study~* Use of GH or Growth hormone releasing factor within six months of starting the study~* Change in lipid lowering or antihypertensive regimen within 3 months of screening~* Fasting blood sugar \>126mg/dL, SGOT \> 2.5 times ULN, Hgb \< 12.0 g/dL, creatinine \> 1.4 mg/dL, FSH \> 20 IU/L in women, or CD4 count \< 200~* Carpal tunnel syndrome~* Severe chronic illness or active malignancy or history of pituitary malignancy or history of colon cancer~* For men, history of prostate cancer or evidence of prostate malignancy by PSA \> 5ng/mL~* Prior history of hypopituitarism, head irradiation, or any other condition known to affect the GH axis~* positive beta-HCG (women only)~* Oral contraceptives, depo provera, or combined progesterone-estrogen injections, transdermal contraceptive patches, estrogen or progestin coated IUD's within 6 months of the study~* weight \< 110 pounds

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- GH 6mcg/kg/d (Type: EXPERIMENTAL): Recombinant human growth hormone 6mcg/kg SC once daily
- GH 2mg daily (Type: EXPERIMENTAL): Recombinant human growth hormone 2mg SC once daily
- Growth Hormone Releasing Hormone (Type: EXPERIMENTAL): Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).